BHVN Overview

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is18.00 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biohaven Ltd revenue for the last quarter amounts to -130.43M USD, decreased -41.13

Biohaven Ltd. EPS for the last quarter amounts to -149918000.00 USD, decreased -9.46

Biohaven Ltd (BHVN) has 274 emplpoyees as of May 17 2026.

Today BHVN has the market capitalization of 1.32B USD.